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The genesis of cancer is often a slow process and the risk of developing cancer increases with age. Altering a diet that includes
consumption of beneﬁcial phytochemicals can inﬂuence the balance and availability of dietary chemopreventive agents. In
chemopreventive approaches, foods containing chemicals that have anticancer properties can be supplemented in diets to prevent
precancerous lesions from occurring. This necessitates further understanding of how phytochemicals can potently maintain
healthy cells. Fortunately there is a plethora of plant-based phytochemicals although few of them are well studied in terms of
their application as cancer chemopreventive and therapeutic agents. In this analysis we will examine phytochemicals that have
strong chemopreventive and therapeutic properties in vitro as well as the design and modiﬁcation of these bioactive compounds
for preclinical and clinical applications. The increasing potential of combinational approaches using more than one bioactive
dietary compound in chemoprevention or cancer therapy will also be evaluated. Many novel approaches to cancer prevention are
on the horizon, several of which are showing great promise in saving lives in a cost-eﬀective manner.
1.Introduction
The transformation of a normal cell into a cancerous pheno-
typerequiresstagesofinitiation,progression,andpromotion
by altering speciﬁc genes [1–3]. Although predisposition
to cancer cannot be signaled out by a single factor, a
group of factors place some individuals at a higher risk
of acquiring the disease. Most of the high-risk cases may
have a genetic background, but in some instances dietary
choices can dictate the outcome of health. As determined
by population and epidemiological studies, the predominant
forms of cancer and cancer-related deaths are those of the
lung and bronchus, breast, colorectal, and prostate [4, 5].
These cancers are also more prevalent in the western parts
of the world and are much lower in Asian countries. A well-
balanced diet that includes more of vegetables and fruits
with less fat/meat intake is in most cases a staple of many
Asian countries [4, 5]. Many hypotheses have supported that
diet and environment greatly inﬂuence cellular function and
health [6].
Phytochemicals are plant-based chemicals that mediate
their positive health beneﬁts directly, by aﬀecting speciﬁc
molecular targets such as genes, or indirectly as stabilized
conjugatesaﬀectingmetabolicpathways[7].Manygenesplay2 Journal of Oncology
signiﬁcant roles in the cell cycle pathway, and some of these
are altered in cancer cells [1, 2]. The aim of most studies is
to understand and formulate mechanistic pathways by which
these naturally derived chemicals can alter the fate of a cell.
Foracancerouscelltosurvive,itshouldbeabletoproliferate,
obtain energy, and establish angiogenic pathways, in a tumor
mass. Altering genes that aﬀect these pathways can serve as
suitable tools to decrease tumor mass and also allow for
tumor regression. In this paper, the key focus will be on
mechanistic pathways that are regulated by nutraceuticals to
bring about changes in the tumor environment and serve
as alternative approaches for cancer prevention and therapy
(Figure 1).
The study of phytochemicals and the classiﬁcation of
these compounds have been previously reviewed [8]. How-
ever, in this paper only some of the most potent and prom-
ising chemopreventive and therapeutic molecules will be
analyzed, with emphasis on combination therapy of these
with other nutramolecules. Most phytochemicals derived
from dietary sources are classiﬁed under an umbrella of
speciﬁc chemical compounds as detailed in Table 1. These
molecules may not have a nutrient value but are germane
to the function of a cell. Various studies have shown that
these molecules can induce apoptosis, inhibit cellular prolif-
eration, aﬀect angiogenesis, and aﬀect cancer metabolism in
various cancers, all of which are hindrances to tumor growth
(Figure 1)[ 7].
Several of the phytochemicals listed in Table 1 have been
investigated in terms of their curative properties. However,
one must carefully interpret the observed results in vitro
and in vivo before testing the same in a clinical setting. The
reasonsforthisaremanyfold.Testsinculturearepure,inthat
there is only one cell type in the culture plate and all condi-
tions are controlled, including the bioactive compound. In
vivo, however, the scenario changes as there are a host of
other factors that need to be taken into account, including
age, weight, diet, and metabolism of the compound. A
bioactive molecule in culture may be subjected to less
metabolic changes and may be presented to the cell in its
native form. However, in vivo the same compound may be
presented diﬀerently, perhaps as a conjugate, and its mode of
actionmaychangeamongstthemultitudeofothermolecules
in the host’s microenvironment. Many in vivo experiments
also control for the type of diet being administered to the
organism, where the concentrations or plasma availability
can be adjusted. Therefore, what may work well in vitro,
may have no agonistic eﬀects or even antagonistic eﬀects in
vivo, and such discrepancies are often seen when comparing
population and epidemiological studies in terms of chemical
eﬃcacy.
An eﬀective nutraceutical is one that will have a low
nontoxicdosewhilecreatingamagnitudeofchangeintumor
dynamics. This means that at a low dose the compound
should act fast on the tumor load. However, if the time
taken to be eﬀective is slow, the problems faced would be
maintaining a tolerable dose and increasing bioavailability
and stability. A solution to such a problem would be to use
a combinatorial approach to therapy, a bioactive molecule
with an eﬀective synthetic drug or double-nutratherapy
(e.g., curcumin and resveratrol). Once tumor regression sets
in, dietary composition of the molecule can be adjusted.
2.NutraceuticalsandTheirPreventiveand
Therapeutic Roles
2.1. Genistein: A Potent Isoﬂavone. Many phytochemicals
are currently being investigated for their promising anti-
carcinogenic properties. In vitro investigations have shown
that some compounds exert their antitumor functions at
much higher concentrations and that dietary consumption
is insuﬃcient to achieve such eﬀective concentrations at
the tumor site. Therefore, the mode of delivery is a very
important factor that needs to be considered at clinical trials
andduringinvivostudies.Thenontoxicpropertiesofnatural
compounds are essential to the design of a formulated
therapy. However, evidence along several lines of treatment
has shown that some compounds are preferentially more
potent in activity when administered early in life [9, 10]. For
instance, soy-based prevention of breast cancer is thought to
be more successful when soy products and their derivatives
are consumed in early development [9].
Isoﬂavones are a group of phytochemicals that are pre-
dominant constituents of a soy-based diet [9, 10]. Among
isoﬂavones, the three major constituents that have been
shown to have remarkable inﬂuences in cancer prevention
and therapy are genistein, diadzein, and glycitin [11].
They are collectively grouped as phytoestrogens for their
weak estrogen-like activity and bind preferentially to ER-
β receptors [12–15]. Evidence of antiproliferative activity
of genistein in vitro stems from its ability to inhibit the
tyrosine kinase enzyme that is most often upregulated in
cancer cells [16, 17]. As a chemopreventive agent, genistein is
thought to inﬂuence the diﬀerentiation process of mammary
tissue. It is believed that early diﬀerentiation of mammary
tissue into terminal buds, as seen in rats, serves as a
chemopreventive strategy as it reduces the susceptibility of
the epithelial cells in the ducts to carcinogens or estrogen
and the ontogeny process [9]. Many aggressive cancers have
altered epidermal growth factor (EGF) receptors on their
cell surface allowing for a continuous downstream signaling
pathway for cell division [18, 19]. This is interesting, as
genistein can serve as a two-fold approach molecule for
prevention and treatment. When EGF binds to its receptors,
tyrosine kinase activation results in the phoshorylation of
tyrosine residues of proteins involved in downstream cell
signaling pathways that trigger cell division. Though studies
have shown that genistein increases the EGF transcript early
in development of mammary tissue, this perhaps is essential
for diﬀerentiation and faster development of the breast
tissue. In the long run this is a positive preventive strategy
of breast lesion formation in ducts [9]. However, as seen in
older rats [9], EGF mRNA decreases. Therefore, a decrease
in EGF mRNA coupled with inhibition of tyrosine kinase by
genistein would profoundly decrease tumor growth as cell
signaling pathways are crucial to tumor maintenance.
Numerous studies have highlighted the antiproliferative
role of genistein in various cancers; however, there are someJournal of Oncology 3
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Figure1:Cellularpathwaysaﬀectedbytheactivitiesofbioactivecomponentsindietarysources.Ofthenaturalcompoundspresentindietary
sources, some are more involved in regulating chemopreventive pathways and some are more eﬀective in inﬂuencing chemotherapeutic
pathways. However, a few of the bioactive molecules found to date can impart both chemopreventive and therapeutic eﬀects, such as EGCG
and genistein. Compound combinations as discussed in the paper that can aﬀect diﬀerent pathways are shown and can have profound eﬀects
on tumor growth and inhibition.
Table 1: Classiﬁcation of nutrients as phytochemicals and their major food source availability.
Phytochemical
class Bioactive compound Source ∗Molecular formula Reference
Alkaloid Caﬀeine Cacao, tea, coﬀee C8H10N4O2 [20]
Theophylline Cacao, tea, coﬀee C7H8N4O2
Monoterpenes Limonene Citrus oils from orange, lemon,
mandarin, lime, and grapefruit C10H16 [21]
Organosulﬁdes
Allicin Garlic C6H10OS2 [22–25]
Indole-3-carbinol Cabbage C9H11NO2 [26]
Isothiocyanates Broccoli CNS [27]
Sulforaphane Broccoli C6H11NOS2 [28]
Carotenoids Beta-Carotene, lycopene Tomatoes C40H56 [29]
Flavonoids
Epigallocatechin-3-gallate Green tea C29H22O15 [30]
Quercetin Black tea C15H10O7 [31]
Curcumin Turmeric C21H20O6 [32]
Phenolic Acids
Capsaicin Chilli peppers C18H27NO3 [33]
Ellagic acid Black berries, raspberry C14H6O8 [34, 35]
Gallic acid Pomegranate, nuts C7H6O5 [36, 37]
Stilbenes Pterostilbene Blueberries and grapes C16H16O3 [38]
Resveratrol Almonds, blueberries, grapes C14H12O3 [39]
Isoﬂavones Daidzein Soy C15H10O4 [9, 40]
Genistein Soy C15H10O5
∗Molecular formulas obtained through the PUBCHEM COMPOUND Database.4 Journal of Oncology
studies indicating that genistein may increase cell prolifera-
tion [19, 47]. A key point to note is that nutraceuticals can
be eﬀective based on the form of genistein or its dose given at
the time of the study (Tables 2 and 3), especially with respect
to in vitro and in vivo models. Importantly, the downstream
targets of bioactive molecules under investigation need to
be ascertained for each speciﬁc tissue, if overall health
applications are an issue. The nutraceutical may not aﬀect
as p e c i ﬁ cc o m m o np a t h w a yf o rt u m o r so fd i ﬀerent origins.
For example, in breast tissue, EGF may be highly expressed,
but, in colon cells or pancreatic cells, genes that regulate
cell division other than EGF may be aﬀected [48]. Cell
culture experiments using plant-based nutrients depend on
the sensitivity of the cells that are being investigated. When
cell lines are established, they are derived from cancerous
tissues of speciﬁcorgans and are, therefore,cell-type speciﬁc.
This is drastically diﬀerent in a clinical setting where the
moleculehastomediateitsactivityamongstahostofvarious
molecules and cell types. Therefore, the concentration of the
phytonutrient in the supplemented diet will be crucial to its
eﬃcacy in the tumor environment. This can help explain the
discrepancies seen in clinical trials of genistein for diﬀerent
tissues[47,49,50].Outcomesofsomeinvitrostudiessuggest
that, like other bioactive compounds, genistein appears to
have a speciﬁc cut-oﬀ concentration at which this isoﬂavone
can exhibit anticarcinogenic activity (10μMo re v e nh i g h e r )
[48, 51], and it is, therefore, imperative to achieve such
concentrations in vivo.
Isoﬂavones,inparticular,genistein,havebeenextensively
studied as prospective antitumor molecules in the treatment
of prostate cancer [19, 52, 53]. There has been a well
established line of evidence that genistein works against
prostate cancer, but a majority of studies are in vitro in
cultured cells [19, 52–56]. Limited clinical trials have tested
the therapeutic eﬃcacy of genistein in prostate cancer and
those that have revealed inconsistencies in cell proliferation
and tumor growth [57–60]. Given the inconsistencies in
some of the outcomes, emphasis should be on the dose
of the supplement and the form of the nutrient in the
supplement at the time of administration to the patient in
clinical trials. The highest achievable plasma concentration
of isoﬂavones is 1μM through orally administered food
sources. From previous studies, this concentration is not
suﬃcientlysigniﬁcanttobringaboutanticarcinogeniceﬀects
on the tissue. However, thereis ample evidencethat genistein
and other isoﬂavones do exhibit anticancer properties and
inhibit cell proliferation and tumor growth. A clinical study
by Gardner et al. [61] showed that treatment of patients with
dietary supplements (82mg/day aglycone equivalents) of
isoﬂavone yielded a higher concentration of total isoﬂavones
in the prostatic tissues than in serum. Therefore, there is a
possibility of increasing the concentration of isoﬂavones to
anticarcinogenic levels in tissue.
An orally administered dose of isoﬂavones must with-
stand the rigors of the alimentary canal and become
metabolized before they can be made available to tissues.
Most isoﬂavones exist as conjugates rather than in their free
state. This conjugation is perhaps the best way to present
the molecule to the cell in tissues, and the hydrolysis of
the conjugates in the tissue allows available free genis-
tein delivery to the cells, as presented or tested in vitro.
For pharmaceutical companies, it is required to formulate
supplements with precise ratios of individual constituents
of the compound. Unless a very pure form, a capsule or
supplement may contain a mixture of genistein, diadzein,
and glycetin (Tables 1, 2, 3,a n d4). The percentage of each
nutrient in the mixture will have a profound eﬀect on the
bioavailability of the compound after metabolism (Tables 2
and 3). To design such a product is certainly not easy and
is dependent on many factors, but the two essential factors
are the grade/stage of the tumor and the site or origin of
the tissue. Of the two isoﬂavones, diadzein has been shown
to have a lesser apoptotic eﬀect on prostate cancer cells
but can inhibit neoplastic transformation [61]. Therefore, it
would be advantageous to use supplements containing the
two bioactive nutrients as chemopreventive agents.
Of the predominant high-risk cancers, genistein appears
to have a greater aﬀect on prostate cancers [52–54]. Genis-
tein mediates the apoptosis of cancer cells by activating
and/or inhibiting genes and/or enzymes germane to tumor
maintenance (Figure 1,T a b l e4). Some of these important
mechanisms are the inhibition of the activity of tyrosine
kinase, nuclear factor kappa B (NF-κB), and vitamin D
24-hydroxylase [86], activation of tumor suppressor genes,
and modulation of androgen-responsive gene expression,
prostate-speciﬁc antigen (PSA), and the androgen receptor
(Table 4). Of the prominent isoﬂavonones in soy, diadzein
is less eﬀective in its action on prostate cancer, but, unlike
genistein, it is metabolized to equol, an isoﬂavandiol which
has a longer half-life than genistein [87]. The longer half-
life of equol creates the possibility of using this chemical in
combination with other available nutraceuticals, where the
net eﬀect may be synergistic. However, prior preclinical tests
are required to investigate this possibility.
Other dietary compounds are also of great interest
in this regard. In vitro, vitamin D (Vit D) has potent
tumor prevention ability and can induce diﬀerentiation and
apoptosis in some of the most predominant cancers [48].
The use of nutrients as a possible treatment approach is
based on the fact that chemicals occurring naturally will
minimize side eﬀects when applied to a biosystem. However,
the in vitro dose at which Vit D induces its antitumor
propertiescauseshypercalcemicconditionsthatcanpreclude
treatment in patients [49]. In prostate cancer, a leading cause
of cancer deaths in the western parts of the world, androgen
ablation therapy is the choice of treatment. However, as the
cancer becomes aggressive, hormone ablation therapy fails,
andprogression ensuesviaandrogen-independent pathways.
Therefore, alternate therapies are very much in demand.
Vitamin D is an alternate form of treatment in prostate
cancer (PCA) and is shown to induce apoptosis in PCA cells
in vitro. However, all PCA cell lines in vitro are not equally
receptive to the vitamin D treatment or genistein [88]. Cell
lines such as DU145 prostate cancer cells are especially more
resistant as they express high levels of CYP24, an enzyme
that catabolizes Vit D3 into less active metabolites [88]. To
circumvent this problem, a recent study showed that a dual
combination therapy, of DU145 to genistein and Vit D3,Journal of Oncology 5
Table 2: Pharmacokinetic studies evaluating the bioavailability of phytochemicals at given doses.
Phyto
chemical Form Dose Model subject Experimental
setup
Maximum plasma
concentration Half-life (h) Reference
Diadzein Soy beverage
15g
Diadzein:genistein
(9.27:10.51mg)
Human
postmenapausal
women
Clinical
96.31ng/mL 7.68
[40]
Two soy
capsules
Diadzein:genistein
(7.79:22.57mg) 96.02ng/mL 6.67
Genistein Soy beverage
15g
Diadzein:genistein
(9.27: 10.51mg)
Human
postmenapausal
women
Clinical
116.37ng/mL 7.61
[40]
Two soy
capsules
Diadzein:genistein
(7.79:22.57mg) 216.84ng/mL 7.96
Curcumin
glucoronide
Curcumoid
powder form
curcumin
(75%),
demethoxycur-
cumin (23%),
and
bisdemethoxy
curcumin
10g (n = 6)
Healthy human
subjects (5 men
and 7 women)
Clinical
2.04 ± 0.31
6.77 ± 0.83
for total
curcumin
conjugates
[41]
12g (n = 6) 1.40 ± 0.74
Curcumin
sulfate
Curcumoid
powder form
curcumin
(75%),
demethoxycur-
cumin (23%),
and
bisdemethoxy
curcumin
10g (n = 6)
Healthy human
subjects (5 men
and 7 women)
Clinical
1.06 ± 0.40 6.77 ± 0.83
for total
curcumin
conjugates
[41]
12g (n = 6) 0.87 ± 0.44
Quercetin
aglycone
Quercetin 500
plus capsule 500mg of quercetin
Healthy human
subjects (6
males and 4
female)
Clinical
15.4ng/mL 3.47
[42]
Quercetin
conjugates
Quercetin 500
plus capsule 500mg of quercetin 336ng/mL
Not given for
plasma level, but
renal clearance
is 0.835
Resveratol
Uncoated
immediate-
release
caplets
500mg
resveratrol/caplet
Healthy human
subjects
Phase I
clinical test [43, 44]
0.5g 72.6 (48.9)∗ ng/mL 2.85∗
1.0g 117.0 (73.1)ng/mL 8.87 (91.1)
2.5g 268.0 (55.3)ng/mL 4.22 (51.6)
5.0g 538.8 (72.5)ng/mL 8.52 (95.8)
Sulforaphane Broccoli raw 200g
Healthy adult
male subjects Clinical
103 ± 31@,n M 3 . 8± 0.8@
[45] Broccoli
cooked 200g 31 ± 19@ nM 4.6 ± 0.8@
EGCG Beverage
200mL 112mg Healthy human
subjects Clinical
Per dose (L−1)
0.51 × 10−3 ±
0.08 × 10−3
3.2 ± 2.1 [46]
D-Limonene
oxygenated
metabolite
perillic acid
30–40 ounces
of lemonade
447–596mg
D-limonene
Healthy human
subjects Clinical 2.08–13.98μM 12–24 [21]6 Journal of Oncology
Table 2: Continued.
Phyto
chemical Form Dose Model subject Experimental
setup
Maximum plasma
concentration Half-life (h) Reference
Lycopene
Lycopene with
up to 250mL
water
10–120mg Healthy adult
male subjects Clinical
Range between
4.03 and
11.27μg/dL
(0.075–0.210μM)
Range between
28.1 61.6h [29]
∗coeﬃcient of variation; @SD—standard deviation.
increased the sensitivity of the cells to Vit D3 by decreasing
CYP24 expression. What is interesting to note is that the
combination approach not only lowered the eﬀective dose,
but was able to abrogate cell proliferation as well. This
lowered concentration of genistein at 100nM is achieveable
in vivo through dietary sources, and clinical studies would be
required to determine the localization of genistein and Vit
D3 in prostatic tissues.
An in vivo study for colorectal cancer has demonstrated
a similar eﬀect [89], but in this case the mice were given a
single gavage of 250μg of genistein. This mode of nutrient
administration is useful for a preclinical test and probably
hasapplicationsasachemopreventivesupplement.However,
in terms of a clinical setting, patients are often exposed to
a host of other nutrients or isoﬂavones in their diet, and;
therefore, an in vivo model replicating such an environment
with various percentages of isoﬂavones will allow for a
better understanding of concentration and bioavailability of
genistein that can mediate an apoptotic eﬀect and reduce
CYP24 expression in colonic tissues in the presence of
vitamin D.
The antimetastatic properties of genistein are mediated
by altering the expression of NF-κB, and inhibiting the
tyrosine kinase enzyme [17, 90]. Non-small-cell lung cancer
(NSCLC) is a highly aggressive form of lung cancer with a
poor prognosis. Therefore, alternate approaches that drasti-
cally reduce tumor growth are of utmost importance. Acti-
vation of epidermal growth factor receptor tyrosine kinase
(EGFR-TK) enhances the cell signaling pathways allowing
tumor growth. The use of drugs that inhibit EGFR-TK and
aﬀectNF-κB,agenewhosetranscribedproductsareessential
for invasion and metastasis, can induce a more aggressive
approach of reducing tumor size and the spread of the
disease.Aclinicaltherapyshouldbeaimedatreducingtumor
growth and spread by inhibiting mechanisms that contribute
to the activation of metastasis. In NSCLC, genistein remark-
ably enhances the eﬀects of EGFR-TK inhibitors, such as
erlotinib and geﬁtinib, when used in combination with each
of them, respectively. This eﬀect was seen to be mediated
by a marked reduction in NF-κB and others, such as EGFR,
pAkt, COX-2, and PGE(2), essential for regulating genes that
control division, proliferation and metastasis [90]. A few
studies have shown how a combined approach can lower
the eﬀective dose concentration even of chemotherapeutic
drugs, minimizing potential side eﬀects. A study conducted
on breast and pancreatic cells showed that, when the cells
were primed with genistein, lower concentrations of the
chemotherapeutic drugs were needed to signiﬁcantly bring
about growth inhibition and apoptosis than with the drugs
alone. In addition, NF-κB was transcriptionally inhibited in
the combined treatment [90].
From a number of investigations, a common thread of
evidence seems to emerge that considerable variation in the
eﬃcacy of bionutrients in cancer treatment exists and diﬀers
even among the same cell lines tested. The reasons for this
are manyfold (Table 5). Cell lines derived from the same
tissue hypothetically should be sensitive to the same dose or
chemical class of the phytonutrients, but such is not always
the case. Alternate medicinal approaches have an important
task to identify crucial factors that change the sensitivity
of the chemical and determine chemical modiﬁcations that
would be necessary to modulate more synchronized results
across several cell lines expressing similar genotypic and
phenotypic signatures.
2.2. Epigallocatechin-3-gallate (EGCG): A Potent Flavanol.
Of the major food-derived phytochemical constituents
that are extensively studied for their chemopreventive and
chemotherapeutic use, EGCG and genistein are by far the
most investigated. EGCG has been shown to have numerous
anticancer properties which include antiangiogenic activ-
i t yb ya ﬀecting the transcriptional expression of vascular
endothelial growth factor (VEGF) [91], inhibiting tumor
initiation and promotion by inhibiting signal transduction
pathways via [phosphatidyloinositol 3-kinase-Akt kinase-
NF-κB] [92–94], inhibiting EGFR [95], inhibiting Her-
2 receptor phophorylation in breast carcinoma cells that
constitutively expresses Her-2/neu receptor [95], inducing
apoptosis in estrogen receptor-(ER-) independent breast
cancercells[96],causingantimetastaticactivity[97],inhibit-
ing proteasome formation [98], inhibiting glucose-regulated
protein (GRP78) activity [99]; inhibiting insulin-like growth
factor-I receptor (IGF-IR) [100], and preventing invasion of
tumorsbyinducingHMG-boxtranscriptionfactor1(HBP1)
transcriptional repressor, an inhibitor of the Wnt signaling
pathway crucial for tumor-invasive property [101].
The serum level concentrations of EGCG are impor-
tant to ensure that an eﬀective response is seen without
adverse or even tumor-promoting functions. Studies have
shown that high doses of catechins that include a higher
concentration of two prominent compounds, epicatechin
gallate (ECG) and EGCG, induce hypoxia-inducible factor 1
which is responsible for activating genes related to hypoxia
conditions. This allows tumor cell proliferation through
alternate survival pathway mechanisms [102]. Most breast
cancers are ER dependent; however, for breast cancers and
others that are ER independent, EGCG inhibits the growth
of tumor cells through the process of apoptosis [96, 103].Journal of Oncology 7
Table 3: Single-dose clinical studies evaluating the bioavailability of phytochemicals or their conjugated or active metabolites.
Phytochemical Route of
administration Form Bioavailability area
under the curve (AUC) AUC values Reference
Diadzein Oral Soy beverage 107 ± 49.16ng·h/mL Adjusted to the
dose [40]
Soy extract
capsules 142.61 ± 43.94ng·h/mL Adjusted to the
dose [40]
Geistein Oral Soy beverage 121.48 ± 70.98ng·h/mL Adjusted to the
dose [40]
Soy extract
capsules 131.04 ± 60.79ng·h/mL Adjusted to the
dose [40]
Curcumin
conjugates
(glucoronide +
sulfate)
Oral
Curcuminoid
powder extract
capsule form
(10g)
35.33 ± 3.78μg·h/mL Relative [41]
Oral
Curcuminoid
powder extract
capsule form
(12g)
26.57 ± 2.97μg·h/mL Relative [41]
Quercetin aglycone Oral Capsule
(500mg) 62.5ng·h/mL Relative [42]
Quercetin-
conjugated
metabolites
Oral Capsule
(500mg) 2000ng·h/mL Relative [42]
∗Rersveratrol Oral
Caplet ranging
from
Relative for all [43]
0.5g 223.7δ ng·h/mL
1.0g 544.8 (57.2)ng·h/mL
2.5g 78.6 (36.2)ng·h/mL
5.0g 1319 (59.1)ng·h/mL
◦Sulforaphane Oral
200g broccoli
Relative [45]
Raw 495 ± 40nM·h
Cooked 286 ± 139nM·h
EGCG Oral Average 200mL
beverage AUCκ nd [46]
D-Limonene
(perillic acid a
major active
metabolite of
d-Limonene)
Oral 40oz of
Lemonade 5.07 to 32.59μM·hR e l a t i v e [ 62]
Lycopene Oral
Liquid form
(tomato paste)
(AUC)0−96
Relative [29]
10mg 214 ± 124.8μg·h/dL
30mg 416.4 ± 183.9μg·h/dL
60mg 421.7 ± 59.3μg.h/dL
90mg 598.9 ± 396.8μg·h/dL
120mg 655 ± 298.6μg·h/dL
∗AUC value measured for resveratrol was AUC inﬁnity with the coeﬃcient of variance denoted in the brackets against the mean value.
δFor the lowest dose of resveratrol AUC inﬁnity value n = 1.
◦AUC value measured for sulforaphane was AUC0-∞.
κBased on the reference paper a list of various AUC values was given for diﬀerent single doses as experimentally performed by diﬀerent laboratories. Since the
sample numbers were diﬀerent, an average AUC value has not been given for this compound.
nd—not determined.8 Journal of Oncology
Table 4: Assessment of the chemotherapeutic and chemopreventive eﬀects of nutraceuticals in combination studies.
Combination of
nutraceutical Dose used Pathways aﬀected or
mechanistic action Organ of study Phase of
study Model of study Reference
Curcumin +
paclitaxel
50μM/L +
10–50μM/L based
on the gene
assessed
Inactivation of NF-κB
and other metastatic
genes.
Breast
In vitro
Human breast
cancer cells
MDA-MB-435
[63]
Curcumin +
paclitaxel
2% w/w
10mg/kg
Inhibition of
metastasis In vivo
Human breast
cancer xenograft
model
Curcumin +
xanthorrhizol
Synergistic eﬀect in
the range from 5 to
20μg/mL
Induction of
apoptosis Breast In vitro
Human breast
MDA-MB-231
cancer cells
[64]
Curcumin +
docosahexenic acid
Ratio of DHA to
CCM
MCF-7
55:30μM
MCF10A
95:45μM
MDA-MB
35:35μM
SK-BR-3
60:40μM
MDA-MB
50:25μM
Inhibition of
proliferation, more
synergistic in one of
the 5 cell lines tested.
Enhanced uptake of
curcumin by the cells.
Upregulated genes
involved in cell cycle
arrest, apoptosis,
inhibition of
metastasis, and cell
adhesion.
Downregulated genes
involved in metstasis
and invasion.
Breast In vitro
Human breast
cancer cells
SK-BR-3,
MDA-MB-231,
MDA-MB-361,
MCF-7, and
MCF10AT
[65]
Curcumin +
genistein
10μM+2 5μM Change in cell
morphology and
growth inhibition
Breast In vitro
T47D and
[66] 10μM+ 2 5μMM C F - 7
11μM+2 5μM MDA-MB-231
Curcumin +
sulphinosine 15μM+1 0μM
Alter multidrug
resistance genes.
Lung In vitro NCI-H460/R [67]
Alters the cell cycle
with cells inhibited
primarily in the S
G2/M phase of the
cycle
Curcumin +
celecoxib
10–15μM/L +
5μM/L
Inhibition of cell
proliferation and
induction of
apoptosis.
Colon In vitro
HT-29
[68]
Possible inhibition of
Cox-2 pathways or
through non-Cox-2
pathways
IEC-18-K-ras
(Cox-2, high
levels) Caco-2
(COX-2, low
levels), and
SW-480 (no
COX-2)
Coltect +
5-aminosalicylic
acid (ASA)
Coltect only 20μM
Inhibition of tumor
growth by induction
of apoptosis.
Colon
In vitro HT-29 cells
[69]
150mg/kg +
50mg/kg
Inhibits abnormal
crypt formation In vivo
Chemical
induction of
tumors by
1,2-dimethyl
hydrazine (DMH)
model in rats.Journal of Oncology 9
Table 4: Continued.
Combination of
nutraceutical Dose used Pathways aﬀected or
mechanistic action Organ of study Phase of
study Model of study Reference
Curcumin +
PEITC
25μM+1 0μM Additive eﬀectives in
the induction of
apoptosis.
Prostate
In vitro PC-3 C4 cell line [27]
3μM+2 . 5μM
Inhibition of tumor
growth through
inhibition of Akt and
NF-κBp a t h w a y s .
In vivo
NCr-
immunodeﬁcient
(nu/nu) mice
bearing s.c.
xenografts of PC-3
human prostate
cancer cells
[70]
Pure 3—curcumin
+r e s v e r a t r o l+
EGCG;
Individual
compounds,
Percentage
composition in the
diet not deﬁned
Inhibit growth by
inhibiting hedgehog
signaling pathways.
Prostate
In vitro
PC-3, LnCaP and
mouse cell line
TRAMP-C2
[71]
Pure
4—apigenin +
baicalein +
genistein +
quercetin;
Pure 7—Pure 3 +
Pure 4;
Crude 7—soy +
sencha leaves +
turmeric + yucca
roots + saw
palmetto +
chamomile
ﬂowers + gingko
Reduce or delay the
o n s e to ft u m o r s . In vivo
Transgenic
adenocarcinoma of
the mouse prostate
(TRAMP) mice
D-Limonene +
docetaxcel 0 . 2m M+1 . 9n M
Induction of
apoptosis by the
regulation of proteins
involved in
mitochondrial
apoptotic pathways
Prostate In vitro
Human prostate
carcinoma DU-145
and normal
prostate epithelial
PZ-HPV-7 cells
[72]
Tomato powder +
broccoli powder
(10:10) g/100g of
diet
11nM of lycopene
per g of diet and
broccoli powder,
1.6μMo f
glucoraphanin,
5.9μMo f
glucobrassicin,
3.9μMo f
gluconasturtiin,
and 2.1μMo f
neoglucobrassicin.
Reduction of tumor
growth mediated by
reduced cell
proliferation and
induction of
apoptosis
Prostate In vivo
Dunning R3327-H
prostate
adenocarcinoma
model
[73]
Lycopene +
ketosamine
(fructose/amino
acid Fru/His)
1μM/L + 2mM/L
Synergistic eﬀect in
inhibiting cell
proliferation
mediated processes.
Antioxidant activity
to prevent initiation
of tumors.
Prostate
In vitro Mat-Lylu rat cells
[74]
20μM/L +
5.6mM/L
Reduce tumor growth
and volume. In vivo
Subcutaneous
injections of
Mat-Lylu cells in
male Copenhagen
rats10 Journal of Oncology
Table 4: Continued.
Combination of
nutraceutical Dose used Pathways aﬀected or
mechanistic action Organ of study Phase of
study Model of study Reference
Lycopene +
docetaxel
1μM+1n M
Synergistically
enhances the
antiproliferative
eﬀects of docetaxel.
Prostate
In vitro
Human PC-3,
LnCaP, DU145
cells
[75]
15mg/kg lycopene
+1 0m g / k g
docetaxel
Reduced tumor
volume and growth
by aﬀecting the levels
of IG-FR receptor that
is highly expressed in
a majority of prostate
tumors. Inhibited Akt
signaling and
suppressed surviving
necessary for tumor
growth
In vivo
Xenograft of
DU145 cells in
NCR-nu/nu
(nude) mice
Quercetin chalcone
(QC) and a
pH-modiﬁed citrus
pectin (MCP)
1.6mg/mL +
1.6mg/mL
Reduction in the
growth of solid
primary tumors
Colon In vivo Balb/c mice [76]
Quercetin + EGCG 20μM+0 – 6 0μM
Inhibits the self
renewal capacity of
prostate cancer stem
cells (PCSCs) by
synergistically
inducing apoptosis
decreasing cell
viability in spheroids,
cell migration,
invasion and colony
formation
Prostate In vitro Prostate cancer
stem cells (PCSCs) [31]
Resveratrol +
estrogen (E2) 10μM+1n M
Antagonistic
estrogenic eﬀects in
suppression of
progesterone receptor
Breast In vitro Human MCF-7
cells [39]
Resveratrol +
quercetin +
catechin
Either all at 0.5μM
and
5μM, or 20μM
Synergistically
inhibited cell
proliferation and
induced apoptosis.
Breast
In vitro Human
MDA-MB-231 cells
[77] Inhibited cell cycle
progression with
predominat cell cycle
arrest in the G2 phase
0.5, 5, and
25mg/kg body
weight in a 100-μL
volume
Reduced primary
tumor growth and,
therefore, inhibit
tumor progression
In vivo
Breast cancer
xenografts in
mouse models
Resveratrol +
cyclophosphamide 50μM+5m M
Inhibit cell
proliferation via
capase mediated
cytotoxicity.
Enhanced
proapoptotic genes
Bax, Fas and
suppressed anti
a p o p t o t i cg e n eB c l - 2
Breast In vitro MCF-7 [78]Journal of Oncology 11
Table 4: Continued.
Combination of
nutraceutical Dose used Pathways aﬀected or
mechanistic action Organ of study Phase of
study Model of study Reference
Resveratrol +
n-Butyrate 50μM+2m M / L
Inhibited cell
proliferation and
induced
diﬀerentiation.
Attentuated p27
(Kip1) levels but
enhanced p21
(Waf1/Cip1)
expression.
Colon In vitro Caco-2 [79]
Resveratrol +
5-Fluorouracil
200μM+I C 50
800μM
Inhibited cell
proliferation and
induced apoptosis by
increase in capase 6
activity
Colon In vitro HCT116 p53+/+
and p53−/− [80]
Resveratrol +
genistein
250mg/kg each in
the AIN-76 diet
Suppressed prostate
cancer development
and mediated
apoptosis by aﬀecting
the expression of
steroid-receptor
coactivor-3 and
insulin-like growth
factor-1
Prostate In vivo
Simian Virus-40
T-antigen-(SV-40
Tag-) targeted
probasin promoter
rat model, a
transgenic model
of spontaneously
developing
prostate cancer.
[81]
Genistein +
sulforaphane 5μM/L + 15μM/L
Aﬀected DNA
methyltransferase
activity and reversed
t h eg e n ee x p r e s s i o no f
promoter
hypermethylated
genes of retinoic acid
receptor h (RARb),
RARB, p16INK4a p16
and
O6-methylguanine
methyltransferase
enhanced growth
inhibitory eﬀects
Esophagous In vitro KYSE 510 cells [82]
Sulforaphane +
benzylisothio-
cyanite
10μM+1 0μM
Changed cell
morphology and
inhibited cell
proliferation.
Reduced cell viability
that correlated with
reduced pSTAT3
levels and an increase
in PARP Cleavage
Pancreas In vitro PANC-1 cells [83]
Sulforaphane +
apigenin 10μM+1 0μM
Synergistically
induced phase II
enzyme
UDP-glucoronyl
transferases
(UGT1A1) transcript
but to a lesser eﬀect
the protein level.
Mediates this action
by the induction of
NF-κB
Colon In vitro CaCo-2 [84]12 Journal of Oncology
Table 4: Continued.
Combination of
nutraceutical Dose used Pathways aﬀected or
mechanistic action Organ of study Phase of
study Model of study Reference
Sulforaphane +
3,3 -
diindolylmethane
(DIM)
2.5μM+2 0μM
Has an antagonistic
eﬀe c ta tl o w
concentration on cell
growth.
Colon In vitro
Human colon
cancer 40–16 cell
line randomly
derived from
HCT116 clone
[85]
Total
concentration
40μM
At cytotoxic
concentrations of the
compounds has
synergistic eﬀects on
growth inhibition
Sulforaphane +
dibenzoymethane
(DMB)
AIN-76A diet
supplemented with
300ppm SFN and
0.5% DMB
Blocked colon tumor
development Colon In vivo Male Apc/min+ mice [28]
Table 5: Factors conducive to the anticarcinogenic eﬃcacy of
nutraceuticals.
Factors Possible eﬀects on the bioactive
components in the dietary supplement
Bioavailability
Metabolism
Time taken to achieve maximum
plasma concentration
Maximum plasma concentration,
half-life
Method of
ingestion
Oral
Intraperitoneal
Subcutaneous
Form of ingestion
Powder/capsule
Liquid
Cooked (solid)
Raw (solid)
Formulation Ratio of pure to the compound
conjugates
Stability Preference for an acidic or basic
environment (pH)
Mechanism of
action
Direct via receptors on the cell surface
or into the nuclear region via channels
Indirect conjugated metabolites
aﬀecting parts of metabolic pathways
AsseeninMDA-MB-468ER-negativecells,cellularapoptosis
is mediated by inducing p53 and Bax proteins that enhance
apoptotic functions in cells [96]. Such observations have
been corroborated by in vivo studies using animal models
[97].
Most studies have shown that anticancer properties of
EGCG are mediated at higher doses. However, such doses
may be irrelevant to clinical applications as they may be
physiologically unachievable through dietary consumption.
Therefore, clinical trials should be aimed at achieving
desired anticancer preventive or tumor functions at much
lowered doses. Such outcomes are possible with a dual-drug
approach. One study [95] demonstrated that combining
EGCG with the drug taxol, which is commonly used to
treat breast carcinomas, lowered the eﬀective dose of EGCG,
ranging from 0.1–1.0μg/mL which is a serum obtainable
level through metabolism. This same group showed that
higher doses (30–40μg) of EGCG were required to mediate a
similar eﬀect when used alone [95].
EGCG can be exploited as a chemopreventive agent if
it prevents cancerous lesions from occurring at lower dose
concentrations and for prolonged periods of time. Most
in vitro studies have used relatively high doses of EGCG
and such doses may prove to be more tumor promotive
than preventive in longer exposure time periods. In a study
designed by Pianetti et al. [92], contradictory results on the
eﬀects of EGCG on Her-2/neu overexpressed receptor in
NF639 breast cancer cells was observed. At short exposure
times, EGCG was very eﬀective in reducing cell proliferation,
but at prolonged exposure cells became resistant to EGCG
with increased levels of NF-κB. This observed change in
drug-induced resistance was related to the activation of
mitogen-activated protein kinase. Itappearsthatsingle doses
or one speciﬁc chemical constituent is mostly insuﬃcient to
induce tumor suppression or regression. Such in vitro data
outcomes emphasize that a dual-drug treatment approach is
necessarytotreatthedisease.Thisalsosignalsthatthetiming
of the nutradrug that is administered is important. Perhaps
EGCG should be administered early in treatment, but later
other phytochemicals or drugs, in conjunction with EGCG,
may need to be administered in the treatment regimen. In
their dual-drug treatment of NF639 Her-2/neu breast cancer
cells, Yang et al. found that treating the cells initially with
EGCG lowered cell proliferation and the later introduction
of the MAPK inhibitor, U0126, reduced invasive phenotype
[93].
Most studies determining the anticancer drug properties
of EGCG are preclinical. For better understanding of speciﬁc
EGCG eﬀects, clinical trials should be carefully designed
to include parameters that inﬂuence EGCG eﬀectiveness.
EGCG has diﬀerent roles in ER-dependent versus ER-
independent receptors, and, therefore, the type of diet
needed to emulate in vitro doses need to be clearly under-
stood through clinical trials and careful pharmacokineticJournal of Oncology 13
Table 6: Surface receptors expressed by breast cancer cells that alter their sensitivity to treatment.
Receptors on the surface Cancer type Phenotype Reference
ER PR Her2
Breast cancer cell line
SK-BR-3 Negative Negative Positive Adenocarcinoma Invasive [65]
MDA-MB-231 Negative Negative negative Adenocarcinoma Invasive [65]
MDA-MB-361 Positive Negative Positive Adenocarcinoma Metstasis [65]
MCF-7 Positive Positive Negative Adenocarcinoma Invasive [65]
MCF10AT Positive Isoform B of
PR and not A Variable
Premalignant
model for cancer
development
Premalignant [65]
studies of these doses in healthy individuals, ER-positive
breast cancer patients, and ER-independent tumors.
In testing phytochemicals of the same or diﬀerent class it
is rather uncertain which markers are necessary to determine
comparabledosagevaluesforinvitroversus invivo eﬃcacies.
Formulation of a diet is one of the major deciding factors in
the functional eﬃcacy of a chemical constituent. It deﬁnes
the concentration of the dose that will be available in vivo,
after metabolism, and determines the diet that needs to be
given to achieve such an outcome. Even though single-dose
individual or mixed phytochemical treatments are currently
available to cancer patients, they are relatively new and
much more research in this direction is warranted. One such
therapythatisrapidlygainingimportanceandholdspromise
for future cancer treatments is combination therapies using
plant-based chemical compounds known as nutraceuticals.
3. Combinatorial Therapy: A Promise of
th eF u tur e(SeeT ab le3)
In prevention or treatment, combinatorial approaches can
be of the following types: a phytonutrient and an eﬀective
drug, two or more phytonutrients, a synthetic phytonutrient
and an eﬀective drug, or a synthetic phytonutrient and
a natural nutrient. Studies in the last few decades have
focused attention on unraveling the protective properties
and mechanistic actions of many phytochemicals. Still the
pharmacokinetics of quite a few of these phytochemicals
are not known, and, for a few that are known, there is
much variability based on mode and form of delivery,
dose, and the model organism of study (Tables 2, 3,a n d
4). Another interesting approach to enhancing curative
and preventive properties of these nutrients is combination
therapies. The therapy is based on the factual information
available at hand and using the potent properties of one with
that of another to enhance synergistic or additive actions
(Figure 1). In this paper, groups that have worked with
diﬀerent phytomolecules belonging to a diﬀerent or the
same chemical class of compounds have been analyzed for
their antitumorigenic activities, and the overall results of the
experiments for each group are described in Table 4.
3.1. Curcumin and Taxol (See [63]). Primary breast cancer
cells are commonly treated with the drug taxol. Sus-
tained chemotherapeutic treatment with this drug has
often resulted in drug resistance and tumor progression.
Many chemotherapeutic drugs induce the expression of the
metastaticgeneNF-κBwhichencouragestumorprogression.
Interestingly, natural-based compounds that are pharmaco-
l o g i c a l l ys a f eh a v eb e e ns h o w nt oi n a c t i v a t eN F - κBe x p r e s -
sion. Taxol is a powerful drug in the treatment of cancer
therefore, in order to prevent metastasis, a combination of
Taxol with curcumin has been shown to downregulate the
expression of NF-κB and induce apoptosis.
3.2. Curcumin and Xanthorrhizol (See [64]). As t u d yc o n -
ducted on an invasive breast tumor cell line, MDA-MB-231,
has shown how and when compounds added to the cells
determine the overall eﬃcacy of the treatment. A sequen-
tial addition of curcumin and xanthorrhizol (a rhizomal
sesquiterpenoidofCurcumaxanthorrhiza)incultureresulted
in additive and antagonistic eﬀects depending on which
compound was added ﬁrst to the culture. However, simul-
taneous addition of the compounds resulted in synergistic
eﬀects at lower concentrations and agonistic eﬀects at higher
concentrations. Such experiments provide evidence that the
eﬃcacy of a drug is dependent on dose, time, and how it
is presented to the cells. Therefore, results obtained might
be contradictory if doses used are simply antagonist or
additive.Forasuccessfulcombinationtherapyorprevention,
synergistic doses are more relevant to mediate downstream
eﬀects, as lower concentrations of the test biomolecules will
be required.
3.3. Curcumin and Docosahexaenoic Acid (DHA) (See [65]).
DHA is a dietary compound present in ﬁsh oil that has been
showntohavepotentchemopreventiveaﬀectsagainstcancer.
Chemotherapeutic eﬀects of compounds are often analyzed
using in vitro models. However, what is most often observed
is that all cells from the same tissue sample do not react
the same way to the test compound. It is essential to have
a chemopreventive or therapeutic agent that can induce its
eﬀects on a wide range of cancerous cells arising from the
same tissue. In this study, the authors analyzed ﬁve cell lines14 Journal of Oncology
expressing diﬀerent cell surface receptors (Table 6)w h i c h
make them susceptible to chemotherapeutic compounds but
in diﬀerent ways and to diﬀerent degrees. The combinatorial
synergistic doses for each cell line were diﬀerent, as shown
in the Table 4. In particular, one breast cancer cell line,
SK-BR-3, which is ER-negative exhibited a higher uptake of
curcumin in the presence of DHA. DHA does not directly
contribute to cell inhibition, but the combination of this
compound with curcumin greatly enhances the uptake of
curcumin by the cells. This compound, DHA, can reach a
plasma concentration level of 200μM. Although the focus
of this study was entirely based on the SK-BR-3 cell line,
the eﬀects of reduced synergy on other cell lines in terms
of transcriptome eﬀects need to be investigated. Mammary
tumors may contain a heterogenous population of cells
exhibiting diﬀerent surface receptors. Using combination
therapy should be aimed at reducing the populations of
all these cell types within the tumor site to truly exhibit
antitumor potency with minimal side eﬀects.
3.4. Curcumin and Genistein (See [66]): A Preventive Strategy.
The aim to use natural compounds in diets is to render
the chemopreventive properties of the compounds to the
tissues. Numerous studies have shown that single dosage
of compounds used alone is eﬀective for chemoprevention.
The problem faced is the inability to achieve high serum
concentrations in vivo. Although combination studies are
just beginning to surface as more prominent approaches in
clinical treatment, studies, though limited, have shown that
synergistic eﬀects of the compounds are able to be achieved
at much lower doses than when compounds are used alone.
Especially in cancers that are hormonally regulated, the
tissues are often exposed to external or internal hormonal
stimulation,likeestrogen,asinthecaseofbreasttissue.Envi-
ronmental agents that mimic estrogen-like activity can often
stimulate or initiate the carcinogenic process. Curcumin, a
curcuminoid, and genistein, an isoﬂavone, are derived from
two diﬀerent chemical classes, yet they have been known
to inhibit a variety of tumor types in vitro and in vivo.
Clinical trials of these compounds individually have been
tested [19, 60, 104, 105]. The mechanistic action of the
individual compounds in many diﬀerent cancers has been
investigated as well. However, using these compounds in
combination drastically aﬀects the development of tumors
by mediating changes in shape and growth inhibition. Such
changes were observed both in ER-positive and ER-negative
cells, indicative of the dual use of such a combination in
prevention and therapy.
3.5. Curcumin and Sulﬁnosine (SF) (See [67]). The inef-
fectiveness of certain drugs in prolonged chemotherapy
stems from the resistance that some cancers develop with
time. This is one of the major obstacles in cancer therapy,
especiallyincancersthataremultidrugresistant(MDR).The
problem in ﬁnding a suitable cure for non-small-cell lung
cancers is the MDR phenotype it exhibits. Treating MDR
cells such as non-small-cell lung carcinoma NCI-H460/R
cells with a commonly employed drug, SF (obtained by the
amination and subsequent oxidation of 6-thioguanosine),
in cell cultures has been shown to inhibit cell growth.
This observed cytotoxicity is enhanced several folds when
low doses of the natural compound, curcumin, are used
in combination, which are otherwise ineﬀective unless very
high concentrations are used. These compounds mediate a
synergisticeﬀectinregulatingthecellcyclephasesanddown-
regulate MDR genes, thereby, enhancing tumor regression
phenotypes even in the presence of mutated p53 molecules.
3.6. Curcumin and Celecoxib (See [68]). Cyclooxygenase-
2 (COX-2) expression is central to the carcinogenesis of
colorectal cancers. Compounds that regulate the expression
or activity of COX-2 in cells may be instrumental in
mediating chemotherapeutic eﬀects on the tissue or cells.
Celecoxib is a potent inhibitor of COX-2 and is presumed
t ot a r g e ti t sa c t i v es i t e .H o w e v e r ,p r o l o n g e de x p o s u r et o
celecoxib results in cardiovascular problems. It appears that
monotherapy regimes are very eﬀective in inhibiting cancer
growth, proliferation, metastasis, and invasion, as seen in
numerous in vitro and in vivo models. However, prolonged
exposures at concentrations relatively higher than what can
be achieved with combination doses may result in unwanted
side eﬀects. Testing the eﬃcacy of celecoxib with cucumin
showed that at lower doses of celecoxib it was possible
to enforce synergistic inhibitory growth eﬀects on colon
cells which expressed various levels of COX-2. Like many
other in vitro investigations, this study emphasizes the fact
that combining powerful drugs with naturally available
potent compounds can reduce the dose needed to mediate
potent anticarcinogenic eﬀects with minimal side eﬀects.
Clinically, such studies are relevant as the doses used or
needed are within the physiologically dose range. With colon
cancer having such a high incidence rate in the western
populations, such therapies can be taken as advantage,
and biomolecules having preventive potential against the
formation of precancerous lesions need to be supplemented
in diets of patients at high-risk.
3.7. Coltect and 5-Aminosalicylic Acid (5-ASA) (See [69]).
Coltect is a novel chemotherapeutic dietary drug with a
formulation of curcumin, a turmeric extract (95% curcum-
inoids) mixed with turmeric powder 1:1, green tea (60%
polyphenols and 25% EGCG) in a 2:1 ratio, and 0.1mg/mL
of L-selenomethionine. 5-ASA is an anti-inﬂammatory drug,
which has been shown to have a preventive role in polyp for-
mation that is thought to occur via the inﬂammation process
in conditions like inﬂammatory bowl disorder. Coltect has
been eﬀective against HT-29 human colon adenocarcinoma
grade II cells in vitro, and this nutraceutical complex in
combination with 5-ASA has been shown to inhibit the
formation or growth of chemically induced aberrant crypt
foci (ACF) in rat models. The molecular mechanism by
which this inhibition is mediated is via the inhibition of
C O X - 2p a t h w a y si nH T - 2 9c e l l s ,w h i c hh a sb e e ns u p p o r t e d
by in vitro studies of other groups [106, 107]. However,
growth inhibition can be aﬀected via COX-2-independent
pathways possibly through mechanisms that are regulated by
the functional polyphenol complex in coltect. Such complex
mixtures are of clinical signiﬁcance as many diﬀerent controlJournal of Oncology 15
mechanisms can be regulated by the presence of individual
constituents of the polyphenols which are a part of the
formulated mixture of coltect.
3.8. Phenylethylisothiocynate (PEITC) and Curcumin (See
[27]). Most prostate cancers begin as a hormone-dependent
tumor, and the hormone is primarily androgen. However,
the more aggressive forms of prostate cancer are androgen-
independent and hormonal therapies fail to be eﬀective.
Alternate therapies are, therefore, necessary to treat such
aggressive forms. Most cancerous cells express various sur-
face receptors that propagate cellular growth. Targeting such
receptors can be an eﬀective chemotherapeutic approach.
Curcumin, obtained from Curcumin longa, has been shown
to inhibit the phosphorylation of EGFR, inhibit the Akt
signaling pathway, and negatively regulate NF-κB. It is an
eﬀective molecule against prostate cancer. Phenylethylisoth-
iocyanate, a phytochemical in cruciferous vegetables, has
been shown to inhibit prostate cancer cell growth in vitro
and this observation has been supported by epidemiological
studies showing that consumption of cruciferous vegetables
has an inverse eﬀect on prostate cancer risk. When two
bioactive molecules with similar eﬀects are used in treating
hormonally independent tumors in aﬀecting receptor medi-
ated signaling, the eﬀects are more pronounced than when
used as individual compounds. With PEITC and curcumin,
the observed eﬀect was more additive than synergistic,
but cell growth inhibition was profoundly aﬀected by the
inhibition of NF-κB pathways and Akt signaling pathways.
Such responses were seen at lower physiological achievable
doses. These results were corroborated by in vivo studies
in mice using human PC-3 prostate cancer cells [70]. Since
EGCG has similar eﬀects on prostate cancer cells, EGCG
could also possibly serve as a substitute in place of curcumin
for such a treatment strategy.
4. D-Limonene andIts Combination Therapies
(SeeTable3)
Although a few studies have shown that D-limonene, an
abundant monoterpene in citrus oils, exhibits antimitogenic
activity, its alcohol-derivated perillyl alchohol (PA) has a
greater inhibitory eﬀect on cell migration in cancerous
cells [108]. A study by Reddy et al. [108] used subtoxic
doses of PA to determine this eﬀect. Further preclinical
studies are necessary to determine the eﬀective yet nontoxic
serum/tissue concentration that can be achieved from a diet
rich in citrus intake, in conjunction with phytonutrients of
the same class or a diﬀe r e n tc l a s s .N o tm u c hi sk n o w na b o u t
the percentage composition of D-limonene and its metab-
olized constituents that are required to achieve an eﬀective
monterpene anticarcinogenic activity. In comparison to its
oxygenated derivatives, limonene has the least cytotoxic
eﬀect on both noncancerous and cancerous breast cell lines
and, therefore, can be applicable in chemoprevention [109].
D-limonene appears to be more eﬀective against chem-
ically induced colonic crypt foci [110]. These foci are
preneoplastic lesions and are biomarkers for the progression
into colon cancer. In colonic crypts that are chemically
induced, limonene asserts its eﬀect by inhibiting the activity
of ornithine decarboxylase, an enzyme essential for the
polyamine biosynthesis pathway. This pathway regulates
the cell cycle, and D-limonene-dependent inhibition of
ornithine decarboxylase (ODC) encourages an antiprolifer-
ative activity. If aberrant crypt foci are the initial markers
forcoloncarcinogenesis,andD-Limoneneanditsderivatives
assert their roles against initiation and promotion phases of
cancer, then a diet rich in citrus foods can prevent crypt for-
mation. Therefore, D-limonene appears to have potential as
a chemopreventive agent in colon carcinogenesis. However,
in vivo studies often do not correlate with results in vitro
for many of the reasons discussed earlier. Once the intake
of a compound is deemed safe for human consumption,
it is imperative to analyze and study the mechanistic and
metabolic functions in human subjects to determine the
eﬃcacy of the nutrient in question. As in the case of under-
standinglimoneneprotectionagainstcoloniccarcinogenesis,
the studies were performed on rats and for shorter exposure
time to the compound or its derivatives. Therefore, further
in vivo models are required to determine the toxicity of
the treatment for longer periods of time, as D-limonene is
nontoxic but its alcohol derivatives could be toxic.
4.1. D-Limonene and Docetaxcel (See [72]). Many combina-
tion studies are underway to determine an eﬀective approach
in treating advanced and aggressive prostate cancers. Doc-
etaxel, a synthetic derivative of taxol, is primarily used to
inhibit the microtubular structures in cancerous cells that
support cell division. In addition to its role as a microtubule
disruptive molecule, it has a host of inhibitory actions
on genes which regulate cell proliferation, mitotic spindle
formation, transcription factors, and oncogenesis. It also
upregulates genes involved in apoptosis and cell cycle pro-
gression in prostate cancer. D-Limonene, discussed earlier
has been shown to have anti-prostate carcinogenic eﬀects at
low dose concentrations. Logically; therefore, combining the
two compounds may have a plethora of positive antitumor
functionalities. In a study by Rabi and Bishayee [72], the
combined treatment enhanced the sensitivity of DU145
prostate cancer cells that are known to be apoptotic resistant.
This enhanced sensitivity was thought to be mediated by
reactive oxygen species (ROS) generation and activation of
caspase 3 and 9. Such a positive in vitro outcome warrants
further investigations in vivo, in models that mimic the
progression of the disease, before it can be used in dietary
supplements for therapy.
4.2. Lycopene and Fru/His (See [74, 111–114]). Serum
lycopene (a carotenoid) levels have been shown to have
an inverse correlation with prostate cancer risk. A diet-
based population study showed that, of all the carotenoids
assessed, high serum lycopene levels showed a statistically
signiﬁcant lower prostate cancer risk. Further analysis of
their data revealed that lower serum lycopene levels in
conjunction with β-carotene supplements were eﬀective
against lowering the risk of prostate cancer, suggestive for
a combinatorial therapy [111]. Certain dietary compounds16 Journal of Oncology
can be the source of cancer formation as seen with prostate
cancer. It is believed that the nonfat portion of milk and
excess calcium are some main factors in prostate cancer
risk [112]. Numerous in vitro studies have shown that
carotenoids have a greater inﬂuence in reducing tumors of
the prostate origin, and lycopene and 1,2-dihydroxyvitamin
D3 are at the forefront as risk reduction factors. In addition
to their role as potent inhibitors of prostate cancer growth,
they are biologically safe and cheaper forms of treatment.
1,2-dihydroxyvitamin D3 and lycopene have physiologically
diﬀerent roles, but combined they modulate pathways to
synergistically inhibit proliferation and diﬀerentiation at
much lower concentrations [113] and bear additive eﬀects
on cell cycle progression.
The assessments that lycopene is a safe dietary molecule
with anticancer properties is supported by a number of
population epidemiological and cohort-based studies [112].
However, it is important to ensure that the statistical models
used are able to adjust for many parameters for a true
signiﬁcant outcome. Regardless of the statistical model
employed in these assessment studies, lycopene has emerged
as a potent risk-reducing factor of prostate cancer and
has been even supported by a study that was carried out
across 28 countries. Intervention combination studies have
not yet been performed. However, in vivo-based studies
in mice models have shown that lycopene administered
in the form of tomato powder and broccoli powder in
a 10:10 ratio, increases its serum concentration to about
538nM/g with about 0.4nM/g concentrated in the prostate
tissue itself. Diet-based intervention studies are required
to determine the formulated diet required to improve the
availabilityintheserumofpatientsandenhancethelocalized
concentration of the molecule in the tissue. Such a diet-
based treatment may serve as a suitable chemopreventive
approachagainstprostatecancerorwithpatientsathigh-risk
of the disease. Even though bioactive molecules successfully
work in administering their protective functions in vitro,
it appears through in vivo studies that diet and availability
crucially dictate outcomes. A critical question to be asked is
what factors constitute a perfect blend of bioactive mixtures.
With the current research thus far, it is hard to address
what the cut-oﬀ ratios are that need to be used in a diet
that contain mixtures of potent nutraceuticals to coordinate
similar eﬀects clinically. Possibly a slight change in con-
centration of even one of the eﬀective biomolecules may
render the mixture ineﬀective in its function. It is rather an
importanttaskforpharmaceuticalchemistsandnutritionists
to determine the ratios of eﬀective biomolecules in a mixture
and determine the pharmacokinetics and dynamics of that
mixture.
Fru/His, a ketosamine, is also a derived product from
tomatoes obtained by the reaction of a carbohydrate with an
amino acid. This particular ketosamine has been found to
assert chemopreventive eﬀects by synergistically enhancing
the activity of lycopene, by neutralizing ROS species and
inhibiting DNA damage. Therefore, the complex of these
two molecules may have a pivotal role in prostate cancer
prevention. Although a rat model was used to determine
the results of the treatment and pharmacokinetics of the
compound are still not known, the combination of the two
seemed to preferentially localize in the prostate more than in
other tissues that were tested [74].
Occasionally, a combination may fail to incite anticar-
cinogenic eﬀects as was seen by Mossine et al. [114]. Their
experiments were conducted on the prostate adenocarci-
nomaratmodelthatwasusedbyothergroups,andtheirdata
had contradictory results to the eﬀective action of lycopene
itself and in conjunction with other micronutrients. Their
study revealed that lycopene was not able to inhibit or reduce
tumor load alone or in combination and that selenium
alone in the mixture was able to induce antitumorigenic
eﬀects. Such outcomes are important as they open up
m o r eq u e s t i o n sa st ow h yam o l e c u l et h a ta ﬀects a given
pathway behaves diﬀerently when tested within the same
experimental model. Is it always dose or concentration or
does molecule preparation and delivery impart eﬀects on the
eﬃcacy of a drug?
4.3. Lycopene and Docetaxel (See [75]). D o c e t a x e li sap o t e n t
chemotherapeuticdrugthatisclinicallyusedtotreatpatients
with advanced metastatic prostate cancers. Although the
drug extends survival, it is for a very limited time period
and with a poor prognosis. Lycopene, a natural compound,
has been shown to have strong cancer inhibitory properties
against the prostate tissue. One study tested the possibility
to use this combination of compounds to enhance survival
of patients that were detected with aggressive, androgen-
independent tumors. As predicted, docetaxel inhibited
tumor growth in nude mice that bore tumor xenografts of
human DU 145 cells. Analysis of molecular mechanisms
revealed that the action of docetaxel was on regulating
the insulin-like growth factor receptor (IGFR) pathway by
suppressing IGF, and this eﬀect was synergistically enhanced
in the presence of lycopene. Together the molecules asserted
negative downstream eﬀects on Akt signaling pathways and
suppressed survivin, products of which have been known
to maintain tumor growth and enhance metastasis. Clinical
trials using this combination may prove eﬀective in treating
patients that express high levels of IGFR in the prostate
tumor and extend survival for a longer duration than what
is possibly achieved by docetaxel alone, which is about 18–20
months.
5. EGCGand Quercetin (See[31])
EGCG exhibits strong chemopreventive and therapeutic
activities as it inﬂuences many pathways as shown in
Figure 1. Some of the mechanistic pathways are involved
in regulating the levels of Bcl2, survivin, and XIAP and
activation of caspase-3/7 to induce apoptosis. EGCG is also
involved in inhibiting genes that are required for transition
from epithelial to mesenchymal cells and retards migration
and invasion which are primarily advantageous in terms
of controlling aggressive tumors. EGCG mediates such
synergistic actions in conjunction with quercetin to retard
the self-renewal properties of cancer stem cells (CSCs), a
population that, if inhibited, can inﬂuence tumor regression.
Quercetin,apolyphenol,downregulatestheexpressionoftheJournal of Oncology 17
heat shock protein (Hsp90) known to inﬂuence apoptosis
and growth inhibition of prostate tumors. Therefore, the
combination of these molecules modulates their respective
therapeutic eﬀects to mediate synergistic growth retardation
of CSCs. The study by Tang et al. [31] used relatively
higher concentrations of EGCG (60μM) in the presence of
20μM quercetin. Probably concentrations of EGCG that can
mediate similar synergistic levels, albeit at lower doses, need
tobeinvestigated,andthetherapeuticpotentialacrosscancer
stems cells of other origins need to be assessed if clinical
applications are to be considered.
6. Resveratrol and Estrogen (See [39])
Selective estrogen receptor modulators that are used in
the clinical treatment of breast cancers display dual ago-
nist/antagonisteﬀectsinthetissues,especiallyincanceriniti-
ation and progression. Drugs like tamoxifen emulate antag-
onistic eﬀects on estrogen to contain the tumor. Agonistic-
estrogen-like activity can in some instances enhance tumor
progression which is not desired in most clinical treatments.
Resveratrol, a polyphenolic compound abundant in grape
skin and grape products including wine, is known to have
chemopreventive properties as supported by numerous in
vitroandinvivostudies.However,basedontheexperimental
cell type, resveratrol induces either agonistic or antagonistic
eﬀectsthatcanbeweakorverypronounced.Resveratrolago-
nistic eﬀects are totally reversed in the presence of estrogen,
possibly mediated through estrogen receptor β. This reversal
of eﬀects is pertinent to prevention of breast cancer lesions
in ducts that could become long-term neoplastic and can-
cerous. Of its many cancer protective functions, resveratrol
in combination with glucan are potent immunomodulators
by upregulating Cdc42 expression [115]. When natural
compounds exhibit multi-chemopreventive properties, con-
jugation therapies are advantageous over monotherapies.
Albeit not clinically tested, harnessing cancer preventive and
immune modulating functions of nutraceuticals seems to be
a plausible approach to targeting hormonally independent
aggressive tumors.
6.1. Resveratrol, Quercetin and Catechin (See Table 4 and
[77]). T h ep r o t e c t i v ef u n c t i o n so fp o l y p h e n o l sa r em a n y -
fold. Numerous studies have analyzed their protective and
therapeutic functions in vitro on tumor initiation that was
chemically induced or in vivo via cellular implanted tumor
formation. Few studies have established the functions of
combined polyphenols on established tumors, as the major-
ity of investigations have focused on individual mechanistic
eﬀects of the compounds. Dietary serum concentrations
are inﬂuenced by the individual percentage of biomolecules
present in the diet. Therefore, individual protective assess-
mentsofacompound showhigherdose requirements,whilst
mixtures may require lower doses to achieve the same eﬀects.
Additive and synergistic eﬀects of compounds occur if their
individual functions are enhanced in the presence of other
molecules, perhaps by reinforcing the serum stability and
availability of the various compounds in the mixture. Such
observations were seen in both in vitro and in vivo testing
of a mixture of three polyphenols, resveratrol, quercetin, and
catechin, albeit pharmacokinetics studies are warranted.
6.2. Resveratrol and Cyclophosphamide (See [78]). Cyclo-
phosphamide, a neoplastic drug, has a broad spectrum of
activity on a variety of cancers, including breast cancers. The
shortfall of the drug is its myriad of toxic eﬀects on other
systems. Dose reduction of the compound would be a means
of reducing its toxicity without compensating its anticar-
cinogenic activity. Resveratrol has been shown to success-
fully lower the eﬀective dose of cyclophosphamide without
altering its anticarcinogenic activity. Both of the compounds
together synergistically enhance caspase-mediated cytotoxic
activity, as demonstrated in MCF-7 cells, an aggressive breast
cancer cell line (Table 4). The combination therapy resulted
in the upregulation of p53, proapoptotic genes, Bax and Fas,
and downregulation of antiapoptotic gene Bcl-2, suggestive
of an apoptotic mechanism involved in cell death.
6.3. Resveratrol and n-Butyrate (See [79]). n-Butyrate is a
short chain fatty acid produced by bacterial fermentation of
ﬁber in the colon. The compound is a known diﬀerentiating
agentandinducesanepithelialphenotypeincertaincultured
cells. n-butyrate is a potent histone deacetylase (HDAC)
inhibitor as well and one of its diﬀerentiation-inducing
properties stems from its ability to inhibit HDACs. Resver-
atrol, discussed above, induces apoptosis through other
mechanistic pathways. The combination of two bioactive
molecules inﬂuencing apoptosis via diﬀerent mechanistic
pathways may associate to render an apoptotic phenotype
in cancerous cells and inhibit tumor formation and pro-
gression. The 2mM dose of n-butyrate used in the Wolter
and Stein study [79] is probably much higher than what can
be physiologically achieved. This dose is probably suitable
for treatment of colon cancers where higher molar doses
of n-butyrate are possible. However, n-butyrate is highly
unstable, and its serum concentrations are lower than 2mM.
Since this molecule is a diﬀerentiating agent, its clinical use
in treatment of other cancers is relevant. However, such
therapies require absolute lower eﬀective doses and can
probably be achieved by combining with molecules other
than resveratrol or modifying the compound to speciﬁc
conjugates to reach serum concentration levels.
6.4. Resveratrol and 5-Fluorouracil (5-FU) (See [80]). 5-
ﬂuorouracil inhibits thymidylate synthase, prevents DNA
proliferation, and induces DNA damage-related apoptosis in
colon cancer cells. Phase I clinical trials using a combination
of resveratrol and grape powder have shown that resveratrol
at low doses inhibit Wnt,ag e n et h a ti su p r e g u l a t e di n
colon cancers. Taking advantage of therapeutic eﬀects of
nutraceuticals, combined therapy of aforementioned resver-
atrol with 5-FU surfaces as a principal strategy in treating
colon cancers. When used in combination, the presumption
is that either additive or synergistic eﬀects of the two could
mediate tumor inhibition by modulating their individual
apoptotic eﬀects. The concern in using resveratrol is that
higher concentrations of the doses are required in the18 Journal of Oncology
treatment which clinically may not be reached through
dietary consumption.
6.5. Genistein and Resveratrol (See [81]). Genistein and
resveratrol as individual phytochemicals are very eﬀective in
the treatment and prevention of prostate cancer progression
in rodent studies. Poorly diﬀerentiated prostate cancers
often fail to respond to androgen-dependent treatments,
and alternate treatments are required. Androgen receptors
likewise have two functional roles, one as a tumor suppressor
in normal prostate tissue and the other as an oncogene in
neoplastic transformation, where it is altered either by muta-
tionsorDNAdamage.Genisteinandresveratrolusedinanin
vivorat-based study, modeled to understand the mechanistic
action of combined treatments in the progression of prostate
cancer,showedthattheyhadmorepronouncedeﬀects,albeit
notsynergistic.Thestatisticallysigniﬁcantadditivefunctions
of reducing cell proliferation through mechanisms that
regulate the androgen receptor levels and IGF-1, a biomarker
found in patient serums with progressive and aggressive
prostate cancers were achieved in combined therapies over
the monotherapy regimes. Interestingly, the combination of
genisteinandresveratrolincreasedserumavailabilityofboth,
but higher concentrations of resveratrol were achievable as
compared to the single-dose regimen. Perhaps, absorption
and stability of resveratrol were profoundly aﬀected in a
combined environment, which is clinically a clear advantage.
The doses used in the study are physiologically safe and
achievable in vivo by consumption of a soy-based diet high
in the percentage of genistein. However, resveratrol is found
in low levels in grape-based dietary products, and, therefore;
a pure supplement of the compound is necessary in case that
higher doses are required.
7. GenisteinandSulforaphane (SFN)(See [82])
Previousstudies haveshownthatEGCG,amajorpolyphenol
in green tea, can inhibit tumor growth through mechanisms
that alter DNA methylation activity, reversing the expression
of silenced genes involved in tumor inhibition in cancer
cells. Hypomethylation of the promoters that are CpG-rich
is more likely to be transcribed, with an exception of few
like hTERT, the regulatory gene of telomerase [82, 116–119].
Epigeneticsisamechanismthathasbeenstudiedfordecades,
and factors that regulate epigenetics are now believed to
be very important as treatment possibilities in controlling
tumors. DNA methylation and histone deacetylation are
well known epigenetic mechanisms that regulate many of
the genes involved in cancers of various origins. Genis-
tein combined with SFN, an histone deacetylase inhibitor
(HDACI) has been successful in inducing the transcription
of genes involved in regulating cell cycle by reversing the
hypermethylated states of their promoters. This change was
observed at low doses and was enhanced in the presence
of sulforaphane more than that when genistein was used
alone. However, in vivo studies of the same are warranted
to determine epigenetic behavior of the dietary compounds
before applications to human treatments are considered.
7.1. Benzylisothiocynate (BITC) and SFN (See [83]). BITC
and sulforaphane are ITCs derived from cruciferous vegeta-
bles like broccoli. Individually both these molecules exert
potent chemotherapeutic properties strongly supported by
numerous studies. Oddly, even though both are isothio-
cyanates, they exert their therapeutic eﬀects by control-
ling diﬀerent pathways involved in tumorigenic inhibition.
STAT3, a member of the STAT group of transcriptional
factors, is required for early development and is dispensable
in adult tissues. However, there appears to be a correlation
between the constitutive expression of STAT3 and tumor
development, indicative of its role as an oncogene. This
gene appears to have important roles in cell proliferation,
angiogenesis, and metastsis, a crucial requirement of tumor
survival. Both BITC and sulforaphane have cancer inhibitory
eﬀects, aﬀecting independent cell signaling pathways. How-
ever, the sequential combination of the two has been shown
to regulate the STAT3 gene and others (Table 4), thereby,
inducing apoptosis. How dietary molecules are presented
to the cells in vitro is important to its cellular mechanistic
actions. In the study by Hutzen et al. [83], sequential
addition of BITC to the cells after sulforaphane treatment
was performed, which enhanced the reduction of STAT3
levels; however, simultaneous additions were not performed.
Simultaneous additions would be important for any com-
bination study to determine possible synergistic, additive,
or antagonistic eﬀects between the compounds. Preclinical
studies should include various combinatorial interactions of
the nutraceuticals being tested to determine the best way of
using combined molecules in therapy.
7.2. SFN and Apigenin (See [84]). Phase I and Phase II
enzymes are extremely important to cancer prevention.
Dietary foods are sometimes modiﬁed to produce car-
cinogens through metabolism by the action of Phase I
enzymes. Subsequently, the action of Phase II enzymes
rapidly metabolizes these products to more soluble forms
that are eliminated as body waste. Phase II enzymes are more
concentrated in the duodenum and small intestine and less
available in the colon. Increasing the availability of these
enzymes in the colon can get rid of harmful carcinogens
reducing the incidence of colon cancers, and, therefore,
dietary supplements that induce Phase II enzymes would
be promising tools for colon cancer prevention. SFN, an
isothiocyanate, and apigenin, a ﬂavanol, have independent
cancer preventive functions. SFN is a strong inducer of UDP-
27 glucuronyltransferase (UGT1A1). UGT1A1 is a major
player in the detoxiﬁcation process of carcinogens formed
in the body and, therefore, is a potent Phase II enzyme.
Treating nondiﬀerentiated colon cells with a combination of
SFN and apigenin was found to synergistically induce the
expression of UGT1A1 suggesting a possible dietary tool for
colon cancer prevention. The in vitro dose of the individual
compounds used in the study was at physiological safe levels
and can be easily achieved in vivo.
7.3. SFN and 3,3 -Diindolylmethane (DIM) (See [85]). The
importance of investigating the roles of dose combinations
on chemopreventive or therapeutic functions has been wellJournal of Oncology 19
dissected in a study by Pappa et al. [85]. Lower doses of
SFN demonstrate antagonistic eﬀects on cell proliferation
and higher doses of both compounds had synergistic eﬀects.
Synergism of compounds is preferred if the outcome is
tumor regression, but in clinical treatments synergistic
actions should be mediated at safe lower concentrations
rather than at cytotoxic levels. Presumably, the choice of
compounds used, based on the genetic or cellular function
required, is imperative to the success of the treatment.
Possibly, SFN can synergistically inhibit the proliferation of
cancer cells with compounds other than DIM at much lower
doses, which has been investigated in studies using SFN
with ﬂavanols. This clearly highlights the problems of using
combined therapies, especially since dosage is of critical
importance for the success of clinical trials.
7.4. SFN and Dibenzoylmethane (DMB) (See [28]). When
seekingfordietarymoleculeswithpotentialchemoprotective
and therapeutic properties, it is essential to understand how
they mediate their combined action. Based on mechanistic
studies, only compounds that are able to achieve synergistic
or additive inhibitory or inductive actions on cellular
genes, pathways, and/or phenotypes can then be chosen for
treatment, even though their individual actions may be more
pronounced. DMB is antimutagenic. Patients with aberrant
polyp crypt (Apc) mutations are prone to spontaneously
form aberrant polyps in their intestinal tissue, which later
can transform to colorectal cancers. Treatment with DMB
f o u n di nl i c o r i c ec a ne ﬀectively inhibit such mutations in
Apc, thereby protecting individuals from aberrant polyp
formations. This molecule, therefore, has potential in terms
of colon cancer prevention.
S F Nh a sam y r i a do fc h e m o p r e v e n t i v ef u n c t i o n sa ss e e n
before in other studies and in various tissues. A combination
of these two chemopreventive agents will have a profound
impact on individuals that are at high-risk or reduce the
incidence of colon cancers through dietary supplementation.
The study by Shen et al. [28] showed that dietary intake
of SFN and DMB negatively inﬂuenced the incidence and
number of tumors formed in the Apc mice. The combined
doses used were half that of the individual doses. However,
the observed eﬀects were still synergistic at these doses.
Interestingly, the serum and plasma levels of SFN and
DBM were lower in the combined doses than when the
compounds were used individually. Regardless of the low
serum availability, the combination was able to mediate
synergistic tumor inhibitory eﬀects. This has important
clinical signiﬁcance as it is possible to achieve greater tumor
toxic eﬀects at low plasma concentrations. Mechanisms that
inﬂuence such actions at low serum availability need to be
further investigated.
8. FutureDirections
Chemopreventive agents are much sought after as an early
interventional approach to prevent tumor development or to
lower the incidence risk of cancers. Given that the current
available methods of treatment are chemotherapy, radiation,
and surgery, all of which can induce signiﬁcant side eﬀects,
an urgent need for alternate or adjuvant therapies has arisen.
Phytochemicals are relatively safe and abundantly available
from dietary sources. Therefore, alternate medicine aims at
harnessing the protective properties of these nonessential
nutrients toward cancer prevention and treatment. A large
database of studies supports the use of biomolecules in
cancer treatment, albeit a majority of those are in vitro
studies. Regardless of limited in vivo studies and clinical
trials, phytochemicals show great promise in cancer treat-
ment considering their safe use. Caution must be taken
when addressing the eﬃcacy of these molecules in clinical
trials as many factors modulate their eﬀects on cellular
functions as detailed in Table 5. Combinatorial studies
also show great promise, especially when lower nontoxic
doses are required for prolonged periods to mediate potent
chemotherapeutic functions with minimal side eﬀects. Two
of the major problems currently faced are dosage and
delivery. To maintain a constant physiological serum dose
availability,itisimperativethattheagentisconcentratedand
stable in the tissue of concern. Combination technologies
may be a solution to this problem. Nanotechnology is
fast catching pace as the next level of technology in all
spheres of science. Limited in vitro studies have shown
that encapsulating dietary supplements in nanoparticles can
eﬀectively deliver the supplement and increase its stability
and availability. Perhaps research needs to focus on such
possibilities as avenues of using combination therapies.
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